Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Highlights:
Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy.
Concurrence with Alterity’s plan to target early stage MSA patients.
Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA.
Agreement that ATH434 has potential as a disease modifying treatment.
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2021 /PRNewswire/ Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ( Alterity or the Company ) has received guidance from the European Medicines Agency
(EMA) regarding key aspects of the Company’s Phase 2 clinical trial for investigational drug ATH434 in the treatment of Multiple System Atrophy (MSA).
Jeneva Clark | Obituary | Fayette Tribune
fayettetribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fayettetribune.com Daily Mail and Mail on Sunday newspapers.
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share:
Pune, India, June 01, 2021 (GLOBE NEWSWIRE) The global neurological movement disorders market has been estimated to reach a value of USD 12,800 million in 2021 and is projected to grow at a CAGR of 9.80% during the forecast period from 2021 to 2030.
Neurological movement disorders are conditions that impair one s ability to generate and regulate movement. This condition predominantly affects the brain, spinal cord, as well as nerves in the body, resulting in cerebrovascular diseases, adult degenerative diseases, and other complications. The key growth drivers of the movement disorder market are the development of efficient and advanced technology, growing prevalence of neurodegenerative disorders, patent expiration of many blockbuster drugs, and the advent of new technologies globally.